Guides, insights, and updates about clinical trials, patient participation, and research developments.
Complete guide to type 1 diabetes clinical trials in the UK ā immunotherapy, stem cells, and artificial pancreas systems.
Guide to AF clinical trials including pulsed field ablation and novel anticoagulants.
Everything you need to know about dementia trials beyond Alzheimer's disease.
Novel pain modulators, neuromodulation, and digital therapy trials for fibromyalgia.
Microbiome therapies, novel topicals, and laser treatments in clinical research.
Neuromodulation, pharmaceutical, and sound therapy trials for tinnitus.
Next-generation urate-lowering drugs and anti-inflammatory agents for gout.
Gluten desensitisation, vaccines, and enzyme supplements in clinical trials.
Comprehensive guide to bipolar disorder trials. Novel antipsychotics, glutamate modulators, circadian rhythm interventions, and treatment-resistant bipolar research.
MDMA-assisted psychotherapy, trauma-focused CBT trials, complex PTSD research, and novel PTSD treatments in UK clinical trials.
Trials for co-occurring conditions in autism: anxiety, sleep, communication, technology interventions, and quality of life research.
Non-opioid treatments, neuromodulation, cannabinoid medicines, and digital pain management studies in the UK.
CPAP alternatives, hypoglossal nerve stimulation, drug treatments, and novel devices for obstructive sleep apnoea.
CFTR modulators, gene therapy, infection management, and next-generation treatments for all CF mutations.
Comprehensive guide to cancer trials in the UK. Immunotherapy, CAR-T cell therapy, targeted treatments, and how to find and join oncology research.
From psychedelic therapy to digital therapeutics. Find trials for depression, anxiety, PTSD, bipolar disorder, and schizophrenia.
Disease-modifying treatments, neurostimulation, and rehabilitation trials across all major neurological conditions.
Biologics for severe asthma, gene therapy for cystic fibrosis, and novel anti-inflammatory drugs for COPD.
GLP-1 agonists, heart failure advances, diabetes prevention trials, and cardiac gene therapy research.
Biologics, biosimilars, JAK inhibitors, and precision medicine for arthritis, IBD, psoriasis, and lupus.
HIV cure research, hepatitis C elimination, long COVID treatment trials, and antiviral drug development.
CRISPR gene editing, AAV-based therapies, sickle cell disease, haemophilia, and genetic disorder trials.
Ending injection burden for AMD, sustained-release glaucoma implants, and inherited retinal disease gene therapy.
Non-opioid pain drugs, neuromodulation devices, digital pain management, and osteoporosis bone-building therapies.
Endometriosis, breast cancer, ovarian cancer trials. PARP inhibitors, personalised treatment, and closing the gender data gap.
How much you can earn, safety regulation, finding Phase 1 trials, and what to expect as a healthy volunteer.
Checkpoint inhibitors, cancer vaccines, monoclonal antibodies, and adoptive cell therapy. How immunotherapy is transforming cancer treatment across the UK.
From blood cancers to solid tumours. How CAR-T cell engineering works, which conditions have active trials, and what the treatment process involves.
CRISPR gene editing, viral vector gene replacement, and gene silencing. Trials for haemophilia, sickle cell disease, inherited disorders, and cancer.
Smart bombs for cancer. Enhertu, Trodelvy, Padcev, and next-generation ADCs. How they work, which cancers they target, and who is eligible.
Exploiting DNA repair weaknesses in cancer. Olaparib, niraparib, and next-gen PARP inhibitors for ovarian, breast, prostate, and pancreatic cancer.
Semaglutide, tirzepatide, retatrutide, and CagriSema. Beyond weight loss ā cardiovascular protection, kidney disease, NASH, and Alzheimer's trials.
Autologous and allogeneic transplant, haploidentical approaches, and reduced-intensity conditioning. Trials for blood cancers and genetic disorders.
Kinase inhibitors, monoclonal antibodies, and precision oncology. Biomarker-driven trials and the NHS Genomic Medicine Service.
GLP-1 agonists, dual and triple agonists, bariatric surgery, and digital health interventions for weight management. Covers semaglutide, tirzepatide, and next-generation therapies.
SGLT2 inhibitors, ARNI, cardiac gene therapy, stem cell patches, and device trials for HFrEF and HFpEF. The evolving landscape of heart failure treatment.
Differentiated, medullary, and anaplastic thyroid cancer trials. RET inhibitors, BRAF-targeted therapy, RAI-redifferentiation, and immunotherapy for aggressive subtypes.
NMIBC, muscle-invasive, and metastatic urothelial carcinoma trials. Immunotherapy, antibody-drug conjugates (enfortumab vedotin), FGFR3-targeted therapy, and BCG-unresponsive treatments.
Hepatocellular carcinoma (HCC) and cholangiocarcinoma trials. Atezo+bev, FGFR inhibitors, IDH1-targeted therapy, and locoregional approaches.
Gene therapy for SOD1 and C9orf72, antisense oligonucleotides, stem cell therapy, neuroprotective agents, and disease-modifying approaches for ALS.
GnRH antagonists (elagolix, linzagolix), non-hormonal treatments, deep endometriosis surgery, fertility-preserving approaches, and novel pain therapies.
Severe asthma biologics, eosinophilic asthma research, smart inhalers, and digital health interventions. From anti-IL-5 to anti-TSLP therapies.
Thrombectomy expansion, neuroprotection, stem cell therapy, and VR rehabilitation. Acute treatment through to long-term stroke recovery research.
Drug-resistant epilepsy treatments, neurostimulation devices, CBD and cannabis-based medicine, gene therapy, and precision surgical approaches.
Anti-IL-23 biologics, JAK inhibitors, stem cell therapy for fistulas, FMT, and precision medicine approaches for inflammatory bowel disease.
Next-generation biologics, JAK inhibitors, acute severe colitis management, microbiome therapies, and colorectal cancer prevention in UC.
Belimumab, anifrolumab, lupus nephritis treatments, BTK inhibitors, and organ-specific therapies for systemic lupus erythematosus.
Disease-modifying therapies, LRRK2 inhibitors, gene therapy, deep brain stimulation, and alpha-synuclein immunotherapy. The most active Parkinson's research landscape in years.
SGLT2 inhibitors for kidney protection, GLP-1 agonists, dialysis innovations, transplant research, and rare kidney disease therapies. CKD trials across all stages.
IL-23 and IL-17 inhibitors, JAK and TYK2 oral therapies, topical innovations, psoriatic arthritis prevention, and whole-disease approaches to psoriasis management.
CGRP monoclonal antibodies, oral gepants, neuromodulation devices, Botox for chronic migraine, and PACAP receptor antagonists. The full migraine trial landscape.
Muscarinic agonists (xanomeline/trospium), TAAR1 agonists, long-acting injectable antipsychotics, early intervention, and cognitive remediation for schizophrenia.
Romosozumab, anabolic bone therapies, treatment sequencing, fracture prevention, denosumab biosimilars, and secondary osteoporosis from cancer treatment or steroids.
Long-acting injectable ART, HIV cure research ("kick and kill", CRISPR), broadly neutralising antibodies, long-acting PrEP, and ageing with HIV comorbidity trials.
Hepatitis B functional cure (siRNA, capsid inhibitors), hepatitis C elimination, MASH/NAFLD trials, PBC and PSC therapies, and liver fibrosis reversal research.
GAD, PTSD, panic disorder, and social anxiety trials. Novel anxiolytics, digital therapies (VR, AI-CBT), neurostimulation, and psychedelic-assisted therapy.
Next-generation medications, adult ADHD research, digital therapeutics and prescription gaming, neurofeedback, and comorbidity-focused approaches.
Renal denervation, novel antihypertensives (ASI, ARNI, ERA), device-based therapies, digital blood pressure management, and resistant hypertension research.
MIGS devices, sustained-release drug delivery (implants), gene therapy, neuroprotection, and SLT optimisation for open-angle glaucoma.
Gut-brain axis therapies, microbiome interventions (FMT, probiotics), low-FODMAP optimisation, visceral pain mechanisms, and IBS-D/IBS-C specific approaches.
Post-viral fatigue, cognitive rehabilitation, POTS and autonomic dysfunction, immune modulation, and multidisciplinary rehabilitation programmes.
Gene therapy, non-factor therapeutics (emicizumab, fitusiran), extended half-life products, paediatric research, and inhibitor management strategies.
CRISPR gene editing (Casgevy), gene therapy, disease-modifying agents (mitapivat), pain management, paediatric research, and stem cell transplant.
Immunotherapy for MSI-H tumours, KRAS G12C and BRAF-targeted therapy, CAR-T cell therapy, organoid-guided treatment, and AI-driven screening for bowel cancer.
Biologic therapies (dupilumab, lebrikizumab, tralokinumab), JAK inhibitors, novel topical agents (roflumilast, tapinarof), and paediatric eczema research.
CAR-T cell therapy (EGFRvIII, IL13RĪ±2), oncolytic viruses, tumour-treating fields, personalised cancer vaccines, and IDH-targeted therapy for brain tumours.
CAR-T cell therapy for ALL and AML, bispecific antibodies (blinatumomab), FLT3 and IDH inhibitors, venetoclax combinations, and MRD-guided precision treatment.
CAR-T for DLBCL and follicular lymphoma, bispecific antibodies (glofitamab, epcoritamab), checkpoint inhibitors for Hodgkin lymphoma, and novel targeted therapies.
Gene therapy for wet AMD, complement inhibitors (pegcetacoplan, avacincaptad) for dry AMD, stem cell RPE patches, and longer-acting anti-VEGF treatments.
Immunotherapy combinations (anti-PD-1 + anti-CTLA-4), BRAF/MEK targeted therapy, neoadjuvant approaches, TIL therapy, personalised mRNA vaccines, and oncolytic viruses.
PARP inhibitors (olaparib, niraparib), antibody-drug conjugates (mirvetuximab), immunotherapy combinations, CAR-T therapy, and BRCA/HRD-guided treatment.
Find actively recruiting breast cancer clinical trials in the UK. Covers TNBC, HER2+, HR+ subtypes, biomarkers, ADCs, immunotherapy, and UK trial centre locations.
Actively recruiting lung cancer trials in the UK. Find NSCLC, SCLC, EGFR, ALK, KRAS G12C studies. Covers immunotherapy, targeted therapies, and biomarker eligibility.
Discover recruiting prostate cancer trials across the UK. Covers mCRPC, PARP inhibitors, PSMA-targeted therapies, Lu-177, and genetic biomarker testing.
Explore Alzheimer's trials in the UK covering anti-amyloid therapies, tau-targeting drugs, APOE-targeted treatments, and prevention studies for pre-symptomatic stages.
Find T2D clinical trials in the UK covering GLP-1 agonists, SGLT2 inhibitors, diabetes remission studies, and digital health interventions.
Active UK depression trials covering MDD, treatment-resistant depression, psilocybin therapy, ketamine, neuromodulation, and digital therapeutics.
MS trial landscape in the UK covering BTK inhibitors, remyelination therapies, neuroprotection, RRMS, SPMS, and PPMS treatment studies.
UK RA clinical trials covering JAK inhibitors, novel biologic targets, biosimilar trials, and preventive medicine approaches for at-risk individuals.
The truth about clinical trial compensation ā how much you can earn, what's covered, how payments work, tax implications, and red flags to watch for.
You can leave a clinical trial at any time, for any reason. Learn how withdrawal works, what happens to your data, your care, and your compensation.
Walk through the entire screening visit ā what happens, what to bring, which tests to expect, and the questions worth asking. Be prepared and confident.
Separating fact from fiction: the truth about placebos, safety, guinea pig fears, and whether you're locked in once you sign up.
A clear guide to informed consent ā what the form covers, your rights at every stage, common concerns answered, and why you can always walk away.
KRAS G12C and G12D inhibitors, immunotherapy combinations, PARP inhibitors for BRCA-mutant disease, HIPEC, and early detection screening for high-risk individuals.
Immunotherapy combinations, HIF-2Ī± inhibitors (belzutifan), CAR-T targeting CAIX, adjuvant treatment after nephrectomy, and biomarker-guided precision approaches.
EGFR inhibitors (osimertinib and beyond), ALK/ROS1/RET targeted therapy, KRAS G12C inhibitors, immunotherapy combinations, ADCs, and neoadjuvant approaches.
Everything you need to know about clinical trials ā what they are, how they work, the phases involved, and what participation really means for you.